British Scientists call into question juiciola effectiveness of Prozac

1. • A study shows that antidepressants work only in the most serious cases
2. • The report suggests that the effect of these drugs is similar to a placebo

The Prozac and Seroxat are two of the most popular drugs in the world, but their effectiveness is now questioned. A study conducted by the University of Hull (United Kingdom) suggested that the new generation of antidepressants do not benefit the majority of patients to consume. Apparently, this type of medication, which controls the levels of serotonin in the brain, only help those who suffer the most severe cases of depression.

Experts from the United Kingdom and Canada have reviewed nearly half a hundred clinical trials, as well as some unpublished data that the laboratories had not made public so far and they finally had to reveal necessarily to be relied on British law on freedom of information. Ade -
More than those already mentioned, the researchers examined two other drugs, Serzone and Effexor. And the conclusion is that it seems that there are few reasons to prescribe antidepressants except for patients with more severe depression "as -
Nalo Professor Irving Kirsch, who has participated in the study.

The effect of the medication in people suffering from depression lighter is virtually zero and similar to that of a placebo. The research suggests that the impact of these drugs could be basically psycho -
Naturally, to make them feel better their capture by the simple fact of believing in them.

40 MILLION CONSUMERS
Predictably, the laboratories have rejected the results, published in the Public Library of Science publication. A spokesman for the multinational pharmaceutical GlaxoSmithKline, the manufacturer Serotax, argued that the study "has taken into account only a small segment of all available data." Eli Lilly, which markets Prozac, medicine who consume 40 million people around the world, adding that "extensive scientific and medical experiments have demonstrated the effectiveness of antidepressants."

The economic interests at stake are enormous and Tim Kendall, deputy director of the Research Division of the Royal College of Psychiatrists, recalled that the laboratory work published only favorable to their products.

Many experts believe that another type of psychological therapy in which the patient speaks, as the cognitive behavior, would be more productive to deal with depression. Others argue that the new generation of antidepressants carry fewer side effects, though some studies linking these drugs with increased suicides. For now, the recommendation of doctors is that anyone who continue to do so until this medicándose talk with your specialist.